Aglaia Oncology Funds

What they do

Founded in 2004, Aglaia Oncology Funds is a boutique venture capital firm based in Bilthoven, Netherlands. The firm is highly specialized, investing exclusively in early-stage breakthrough inventions that have the potential to transform cancer treatment. Aglaia is known for its hands-on, operator-led approach, having co-founded half of its core portfolio companies. They have built a strong reputation in the European biotech ecosystem for de-risking early-stage science, guiding startups from animal feasibility studies through clinical trials, and maturing them for licensing, acquisition, or IPO.

What they look for

Aglaia invests in early-stage oncology drug development companies with disruptive science that has the potential to transform cancer diagnosis and therapy. They aim to select and mature breakthrough inventions to build tomorrow's leaders in the fight against cancer.

Stage

Pre-seed, Seed, Series A

Sectors

Healthcare, Deeptech

Based

Bilthoven, NL